Results 51 to 60 of about 29,286 (231)

Complementary efficacy of CD127-directed immunotherapy with lusvertikimab and ABL-targeting tyrosine kinase inhibitors in preclinical ABL-class-fusion-positive B-ALL. [PDF]

Hemasphere
HemaSphere, Volume 10, Issue 6, June 2026.
Pinkle D, Cornils M, Dietterle A, Laqua A, Kurschies M, Heymann J, Funke E, Fanter P, Gupta DD, Reimer C, Mahachi DT, Gehlert CL, Winterberg D, Vossen-Gajcy M, Müller X, Balow G, Iben K, Barz M, Bastian L, Baldus C, Kowol M, Kikvadze S, Wurm AA, Logvinova E, Vokuhl C, Schmid JP, Jeremias I, Klausz K, Peipp M, Schrappe M, Baccelli I, Poirier N, Brüggemann M, Cario G, Schewe DM, Lenk L.   +35 more
europepmc   +2 more sources

Dasatinib Induced Avascular Necrosis of Femoral Head in Adult Patient with Chronic Myeloid Leukemia

, 2015
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the presence of the Philadelphia (Ph) chromosome resulting from the reciprocal translocation t(9;22)(q34;q11).
Mohamed A. Yassin, Sarah ELkourashy, Deena S. Mudawi, Hope-Love G. Gutierrez, Deena-Raiza Asaari, Nader Al-Dewik, Hatim El Derhoubi, Ahmed Elsayed, Mohamed Al Musharraf, Shehab F. Mohamed, Ashraf T. Soliman, Abbas H. Moustafa, Abdulqadir J. Nashwan, Radwa M. Hussein, Samah Kohla   +14 more
core   +1 more source

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang, Umar Raza, Jia Song, Junyan Lu, Shun Yao, Xiaohong Liu, Wei Zhang, Shujuan Li   +7 more
wiley   +1 more source

Cardiovascular toxicity induced by TKIs in patients with chronic myeloid leukaemia: Are women and men different?

ESC Heart Failure, Volume 12, Issue 2, Page 1447-1454, April 2025.
This study analyzes 148 patients (66 women and 82 men) with chronic myeloid leukemia treated with tyrosine kinase inhibitors, focusing on cardiovascular adverse events. The risk assessment, performed using the HFA/ICOS score, reveals sex‐specific differences: venous thrombosis is more common in women, while arterial thrombosis predominates in men.
Cristina Madaudo, Daniela Di Lisi, Antonio Cannatà, Federica Manfrè, Celeste Vullo, Marco Santoro, Ciro Botta, Salvatrice Mancuso, Sergio Siragusa, Alfredo Ruggero Galassi, Giuseppina Novo   +10 more
wiley   +1 more source

Transforming growth factor β signaling overcomes dasatinib resistance in lung cancer. [PDF]

PLoS ONE, 2014
Lung cancer is the second most common cancer and the leading cause of cancer-related deaths. Despite recent advances in the development of targeted therapies, patients with advanced disease remain incurable, mostly because metastatic non-small cell lung ...
Edna Gordian, Jiannong Li, Yuri Pevzner, Melanie Mediavilla-Varela, Kimberly Luddy, Kim Ohaegbulam, Kenyon G Daniel, Eric B Haura, Teresita Muñoz-Antonia   +8 more
doaj   +1 more source

Dasatinib-induced pulmonary arterial hypertension

, 2018
Drug-induced (group 1) pulmonary hypertension (PH) is an important subgroup of PH involving dasatinib as a likely related agent, which is a second-generation tyrosine kinase inhibitor (TKI) used in the treatment of chronic myeloid leukaemia (CML).
Eskazan, Ahmet Emre, Nurgül Özgür Yurttaş, Ahmet Emre Eşkazan, Yurttas, Nurgul Ozgur   +3 more
core   +1 more source

Targeted senotherapy improves electrographic and behavioral outcomes in a mouse model of temporal lobe epilepsy

Epilepsia, EarlyView.
Abstract Objective Current pharmacotherapy for temporal lobe epilepsy (TLE) is limited to symptomatic treatment and leaves approximately one third of patients with inadequate seizure control. Discovering disease‐modifying targets is an unmet clinical need. We have previously identified senescent cells (SCs) as one such target. Many drugs that eliminate
David J. McFall, Abbas I. Hussain, Michelle Cho, Patrick A. Forcelli   +3 more
wiley   +1 more source

Dasatinib in First- and Second-Line Therapy of Chronic Myeloid Leukemia: Efficacy, Safety and Quality of Life

Клиническая онкогематология, 2017
Background & Aims. The article presents results of two observational, prospective, multicenter studies “Quality of Life, Symptom Profile, and Adherence to Treatment in Adult Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Receiving ...
Tat’yana Ivanovna Ionova, N. B. Bulieva, O. Yu. Vinogradova, T. A. Gritsenko, L. K. Kozlova, G. B. Kuchma, E. G. Lomaia, E. R. Machyulaitene, T. P. Nikitina, N. V. Novitskaya, A. Yu. Rodionova, E. I. Usacheva, T. V. Shneider   +12 more
doaj   +1 more source

Adverse Health Events in Chronic Myeloid Leukaemia Patients Treated With Tyrosine Kinase Inhibitors 2009–2019: A Real‐World Study From the UK's Haematological Malignancy Research Network

International Journal of Cancer, EarlyView.
Although tyrosine kinase inhibitors (TKIs) improve chronic myeloid leukemia (CML) outcome, long‐term effects remain unclear, particularly in real‐world settings. Here, the authors examined morbidity and mortality in CML patients treated with TKIs between 2009 and 2019 in the United Kingdom.
Eleanor Kane, Alexandra Smith, Debra Howell, Catherine Cargo, Kate Rothwell, Simone Green, Russell Patmore, Eve Roman   +7 more
wiley   +1 more source

Dasatinib-induced chylothorax: a clinical laboratory’s perspective [PDF]

, 2023
Dasatinib; Pleural effusion chylothoraxDasatinib; Derrame pleural quilotóraxDasatinib; Vessament pleural quilotòraxDasatinib is a tyrosine kinase inhibitor drug used for chronic myeloid leukaemia (CML) treatment. Chylothorax has been rarely reported as a
García Martínez, Rafael, Martin Riera, Victor, Guerra-Ruiz, Armando, Ferrer Costa, Roser, Paciucci Barzanti, Rosanna, Ramírez Serra, Clara, Sanz Gea, Clara   +6 more
core